Trial characteristics.

Abbreviations: C, Cetuximab; P, Panitumumab; IRI, irinotecan; OX, oxaliplatin; CAP, capecitabine; 5-Fu, 5-fluorouracil; Bev, bevacizumab; FOLFOX-4, folinic acid+5-Fu+OX; FOLFIRI, folinic acid+5-FU+IRI; CAPOX, CAP+ OX; CAPIRI, CAP+ IRI; FLOX, folinic acid+OX; chemo, chemotherapy.NR, Not reported; RECIST, the Response Evaluation Criteria in Solid Tumors; WHO, World Health Organization.1st, first line treatment, ≥2nd, second or or higher line treatment; 3rd, third line treatment.A* represented all patients but one received moAbs as a second or higher line treatment.A # represented all patients but three received moAbs as second or higher line treatment.